imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. efekt imatinib na wynik przeszczepienia szpiku kostnego nie jest określona. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. doświadczenie z imatinibom u pacjentów z mds/jest msy, związanych z pdgfr genów permutacji-bardzo ograniczony. brak kontrolowanych badań wykazują kliniczną korzyść lub zwiększone tempo dla tych chorób.
vitaminum pp 50 mg polfarmex 50 mg tabletki
polfarmex s.a. - nicotynamidum - tabletki - 50 mg
vitaminum pp 200 mg 200 mg tabletki
polfarmex s.a. - nicotynamidum - tabletki - 200 mg
sofiperla 0,075 mg + 0,03 mg tabletki powlekane
actavis group ptc ehf. - gestodenum + ethinylestradiolum - tabletki powlekane - 0,075 mg + 0,03 mg
astha 0,03 mg + 2 mg tabletki powlekane
aristo pharma sp. z o.o. - ethinylestradiolum + dienogestum - tabletki powlekane - 0,03 mg + 2 mg
polaring (0,12 mg + 0,015 mg)/24 h system terapeutyczny dopochwowy
zakłady farmaceutyczne polpharma s.a. - etonogestrelum + ethinylestradiolum - system terapeutyczny dopochwowy - (0,12 mg + 0,015 mg)/24 h
juliperla 0,075 mg + 0,02 mg tabletki
actavis group ptc ehf. - ethinylestradiolum + gestodenum - tabletki - 0,075 mg + 0,02 mg
mirgi (0,12 mg + 0,015 mg)/24 h system terapeutyczny dopochwowy
zentiva, k.s. - etonogestrelum + ethinylestradiolum - system terapeutyczny dopochwowy - (0,12 mg + 0,015 mg)/24 h
pamidronat medac 3 mg/ml 3 mg/ml koncentrat do sporządzania roztworu do infuzji
medac gesellschaft für klinische spezialpräparate mbh - dinatrii pamidronas - koncentrat do sporządzania roztworu do infuzji - 3 mg/ml
paracetamol aurovitas 500 mg tabletki
aurovitas pharma polska sp. z o.o. - paracetamolum - tabletki - 500 mg